Pfizer Abandons Weight Loss Pill Due to Adverse Effects

Pfizer has decided to abandon a twice-daily obesity treatment after more than half of the patients in a clinical trial stopped taking it due to nausea and vomiting. The pharmaceutical company will instead focus on a once-daily version of the pill, danuglipron. While the mid-stage study showed statistically significant weight loss in adults with obesity, the discontinuation rates and side effects were concerning. Pfizer's decision comes as obesity treatments continue to be a lucrative area of medicine, with rivals Novo Nordisk and Eli Lilly already having injectable drugs on the market.